炎症反应预测高龄急性心肌梗死患者PCI术后主要不良心血管事件的研究进展

doi:10.3969/j.issn.1003-9198.2026.09.016

摘要/Abstract

摘要： 本文聚焦高龄急性心肌梗死(acute myocardial infarction,AMI)患者经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)后主要不良心血管事件(major adverse cardiac events,MACE)的风险,综述炎症反应相关机制、炎症标志物的预测价值及潜在干预策略。现有证据提示,炎症反应可通过影响斑块稳定性、血栓形成及心肌重构等环节增加PCI术后MACE风险;hs-CRP、全身免疫炎症指数等指标对MACE具有一定预测价值。然而,现有研究多来自混合年龄人群,高龄患者的独立证据仍不足,相关联合预测模型尚待建立。

关键词: 老年人, 炎症反应, 急性心肌梗死, 经皮冠状动脉介入治疗, 主要不良心血管事件

Abstract: This review focuses on the risk of major adverse cardiac events (MACE) after percutaneous coronary intervention (PCI) in elderly patients with acute myocardial infarction (AMI), and summarizes the inflammation-related mechanisms, the predictive value of inflammatory biomarkers, and potential therapeutic strategies. Current evidence suggests that inflammation may increase post-PCI MACE risk by impacting plaque stability, thrombosis, and myocardial remodeling. Biomarkers such as high-sensitivity C-reactive protein and the systemic immune-inflammatory index exhibit certain predictive value. However, most existing studies are based on mixed-age populations, and independent evidence in older patients remains insufficient. In addition, integrated predictive models tailored to this population are still lacking.

Key words: aged, inflammatory response, acute myocardial infarction, percutaneous coronary intervention, major adverse cardiac events

中图分类号:

R 542.22

刘颢斐, 秦海东. 炎症反应预测高龄急性心肌梗死患者PCI术后主要不良心血管事件的研究进展[J]. 实用老年医学, 2026, 40(9): 947-951.

LIU Haofei, QIN Haidong. Inflammatory response as a predictor of major adverse cardiovascular events in elderly patients with acute myocardial infarction after percutaneous coronary intervention[J]. Practical Geriatrics, 2026, 40(9): 947-951.

参考文献

[1] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志, 2020, 35(9): 833-854.
[2] 沙琬婧, 杨涛, 周华, 等. 基于住院病案首页信息的急性心肌梗死流行病学特征分析[J]. 中西医结合心脑血管病杂志, 2022, 20(10): 1838-1840.
[3] DAMLUJI A A, FORMAN D E, WANG T Y, et al. Management of acute coronary syndrome in the older adult population: a scientific statement from the American Heart Association[J]. Circulation, 2023, 147(3): e32-e62.
[4] LIBERALE L, BADIMON L, MONTECUCCO F, et al. Inflammation, aging, and cardiovascular disease: JACC review topic of the week[J]. J Am Coll Cardiol, 2022, 79(8): 837-847.
[5] DAMLUJI A A, NANNA M G, MASON P, et al. Coronary artery revascularization in the older adult population: a scientific statement from the American Heart Association[J]. Circulation, 2025, 152(25): e494-e525.
[6] DAMLUJI A A, CHUNG S E, XUE Q L, et al. Frailty and cardiovascular outcomes in the national health and aging trends study[J]. Eur Heart J, 2021, 42(37): 3856-3865.
[7] IMBESI A, GRECO A, SPAGNOLO M, et al. Targeting inflammation after acute myocardial infarction[J]. J Am Coll Cardiol, 2025, 86(15): 1146-1169.
[8] GERHARDT T, SEPPELT C, ABDELWAHED Y S, et al. Culprit plaque morphology determines inflammatory risk and clinical outcomes in acute coronary syndrome[J]. Eur Heart J, 2023, 44(38): 3911-3925.
[9] CHEN R, ZHANG H, TANG B, et al. Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets[J]. Signal Transduct Target Ther, 2024, 9(1): 130.
[10] LIU X, CHEN B, CHEN J, et al. A cardiac-targeted nanozyme interrupts the inflammation-free radical cycle in myocardial infarction[J]. Adv Mater, 2024, 36(2): e2308477.
[11] HAJISHENGALLIS G, CHAVAKIS T. Inflammageing and clonal haematopoiesis interplay and their impact on human disease[J]. Nat Rev Mol Cell Biol, 2026, 27(5): 377-393.
[12] BISCAGLIA S, GUIDUCCI V, ESCANED J, et al. Complete or culprit-only PCI in older patients with myocardial infarction[J]. N Engl J Med, 2023, 389(10): 889-898.
[13] PARK D W, BODEN W E, DE CATERINA R, et al. Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques[J]. Eur Heart J, 2026. DOI: 10.1093/eurheartj/ehag103.
[14] BAY B, TANNER R, GAO M, et al. Residual cholesterol and inflammatory risk in statin-treated patients undergoing percutaneous coronary intervention[J]. Eur Heart J, 2025, 46(32): 3167-3177.
[15] KRALER S, LIBERALE L, TIRANDI A, et al. The junctional protein associated with coronary artery disease predicts adverse cardiovascular events in patients with acute coronary syndromes at high residual risk[J]. Eur Heart J, 2026,47(28):3693-3707.
[16] LUO J, QIN X, ZHANG X, et al. Prognostic implications of systemic immune-inflammation index in myocardial infarction patients with and without diabetes: insights from the NOAFCAMI-SH registry[J]. Cardiovasc Diabetol, 2024, 23(1): 41.
[17] MA M, WU K, SUN T, et al. Impacts of systemic inflammation response index on the prognosis of patients with ischemic heart failure after percutaneous coronary intervention[J]. Front Immunol, 2024, 15: 1324890.
[18] MA F, LI L, XU L, et al. The relationship between systemic inflammation index, systemic immune-inflammatory index, and inflammatory prognostic index and 90-day outcomes in acute ischemic stroke patients treated with intravenous thrombolysis[J]. J Neuroinflammation, 2023, 20(1): 220.
[19] MATTER M A, PANENI F, LIBBY P, et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly[J]. Eur Heart J, 2024, 45(2): 89-103.
[20] SCHMITZ T, HARMEL E, HEIER M, et al. Inflammatory plasma proteins predict short-term mortality in patients with an acute myocardial infarction[J]. J Transl Med, 2022, 20(1): 457.
[21] PAN Y, MA L. Inflammatory markers and physical frailty: towards clinical application[J]. Immun Ageing, 2024, 21(1): 4.
[22] GOUPIL R, DESBIENS L C, MERABTINE A, et al. Subclinical primary aldosteronism and major adverse cardiovascular events: a longitudinal population-based cohort study[J]. Circulation, 2025, 152(13): 913-923.
[23] CHAN K, WAHOME E, TSIACHRISTAS A, et al. Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study[J]. Lancet, 2024, 403(10444): 2606-2618.
[24] LEE M S, SHIN T G, LEE Y, et al. Artificial intelligence applied to electrocardiogram to rule out acute myocardial infarction: the ROMIAE multicentre study[J]. Eur Heart J, 2025, 46(20): 1917-1929.
[25] FAZEL R, YEH R W, COHEN D J, et al. Intravascular imaging during percutaneous coronary intervention: temporal trends and clinical outcomes in the USA[J]. Eur Heart J, 2023, 44(38): 3845-3855.
[26] RIDKER P M, MOORTHY M V, COOK N R, et al. Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women[J]. N Engl J Med, 2024, 391(22): 2087-2097.
[27] KRAAIJENHOF J M, NURMOHAMED N S, NORDESTGAARD A T, et al. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study[J]. Eur Heart J, 2025, 46(39): 3875-3884.
[28] ZHANG W, ZHANG J, WANG Z, et al. Extracellular RIPK3 acts as a damage-associated molecular pattern to exaggerate cardiac ischemia/reperfusion injury[J]. Circulation, 2024, 150(22): 1791-1811.